July 23, 2024 — Liver disease is frighteningly common worldwide. Metabolic dysfunction-associated steatotic liver disease, or MASLD, is an umbrella term describing conditions related to a buildup of fat in the liver. Formerly known as nonalcoholic fatty liver disease, this condition affects 1 in 4 people worldwide. Among those with type 2 diabetes, insulin resistance, obesity, or all three, […]
June 25, 2024 — It’s over. The 84th Scientific Sessions of the American Diabetes Association came to an end yesterday and for anyone interested in obesity, it has given us a lot to absorb. After four days with a steady stream of new information about drugs like the GLP-1 agonists that regulate appetite and adiposity, we are left wondering. […]
June 9, 2024 — At the EASL Congress 2024 in Milan, we witnessed quite a splash of new data on both survodutide and tirzepatide for MASH. Friday and Saturday gave us two headline presentations at the meeting and two publications in the New England Journal of Medicine. Lilly pronounced itself “very pleased” with the results of their SYNERGY-NASH study […]
June 6, 2024 — On the opening day of the EASL Congress in Milan, we got a peek at more details on the results of the phase 2 study of tirzepatide in MASH (metabolic dysfunction associated steatohepatitis). The study, called SYNERGY-NASH, will be the subject of a late-breaking presentation on Saturday at the meeting. But the release of the […]
May 9, 2024 — We’re packing our bags for Venice, where the European Congress on Obesity (ECO 2024) will start in just a few days. A lot will be coming at us in a short space of time, so taking time to set some priorities is essential. Thus, we have a short list of things that we’ll be seeking […]
March 21, 2024 — For an early stage of hepatic steatosis called MASLD, JAMA has just published results from an intriguing study. It is a small RCT showing that low-dose aspirin can significantly reduce fat in the liver of persons with MASLD and without cirrhosis. MASLD is a new acronym for metabolic dysfunction-associated steatotic liver disease. You might know […]
March 16, 2024 — Firsts are worth celebrating. In this case, the cause for celebration is especially great. MASH or metabolic steatohepatitis is a disease that is growing dramatically more common and more harmful to the health of the population. Late this week, FDA approved resmetirom to be the first ever treatment for MASH with fibrosis. Note that the […]
February 27, 2024 — Yet another GLP-1 agonist in development for obesity – survodutide – showed promising results yesterday from a phase 2 clinical trial in MASH. In case you missed the notice, MASH is the new acronym for what we used to label as NASH. We also note that MASLD has replaced NAFLD in the nomenclature alphabet soup […]
February 7, 2024 — Let’s be clear from the start. Hype about “weight loss” drugs is exquisitely unhelpful. This is because weight loss is only an acute effect of new medicines that act on GLP-1 receptors and related pathways that influence obesity. The real need for these medicines is to control a whole range of chronic health problems that […]
December 4, 2023 — By the end of this month, we will be seeing lists of what’s in and what’s out for the coming year. For people whose minds drift toward liver disease, we have an entry. Fatty liver is out and steatotic liver is in. NAFLD goes to the dustbin, replaced by MASLD, while MASH takes over from […]
